Benefits of LDL-C Lowering in High-Risk Patients

Details & Video

Program Time: 30 minutes
Accreditation-CME Credits: This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.
Target Audience: General Practitioners
Program available until: September 25, 2019
Program Preview
Click image above to play the program preview.

Overview & Objectives



Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. DEFINE
    The patient subgroups that will receive the most benefit from PCSK9 inhibition
  2. IDENTIFY
    The benefits of additional LDL-C lowering in patients with peripheral arterial disease



Accreditation

This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.

This program was supported in part by educational funding from Amgen Canada.

Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.

Planning Committee & Faculty

Planning Committee & Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

Brampton, ON
Jeffrey Habert
Jeffrey Habert
M.D., CMFC, FCMF

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine

View disclosures

Toronto, Ontario
Daniel Ngui
Daniel Ngui
B. Sc., PT, M.D., FCMF

Clinical Associate Professor
University of British Columbia

Medical Director
Fraser Street Medical

View disclosures

Vancouver, BC
Marla Shapiro
Marla Shapiro
C.M., M.D.C.M., CMFC, M. Sc. S., FRCPC, FCMF, NCMP

Professor, University of Toronto
Department of Family and Community Medicine

University Health Network
North York General, Mount Sinai

View disclosures

Toronto, Ontario
Marc S. Sabatine
Faculty
Marc S. Sabatine
MD, MPH

Chairman, TIMI Study Group
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine, BWH
Professor of Medicine, HMS
View disclosures

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction1:28
Effects of PCSK9 Inhibitors5:14
Benefit and differences of LDL-C lowering in patient subgroups1:03
Subgroup: Patients with low LDL-C2:24
Subgroup: Patients with diabetes1:57
Subgroup: Patients with prior MI or multivessel coronary disease4:56
Subgroup: Patients with peripheral artery disease1:39
Summary1:30


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • Sabatine MS et al. NEJM 2017;376:1713-22
  • Schewartz, G et al. “The ODYSSEY OUTCOMES Trial: Topline Results. Alirocumab in Patients After Acute Coronary Syndrome.”
  • American College of Cardiology - 67th Scientific Sessions. Orlando, Florida, 2018.
  • Giugliano RP et al. and Sabatine MS. JAMA Cardiol 2017;2:1385-91
  • Sabatine MS, Leiter LA et al. Lancet Diab & Endo 2017;5;941-50
  • Ray KK et al. American Diabetes Association 2018, Scientific Sessions – Orlando, FL
  • Sabatine MS et al. Circulation 2018;epub ahead of print
  • Bonaca MP et al. & Sabatine MS. Circulation 2018;137:338-50